What if you could use #AI to design a new gene editor? In an exciting proof-of-concept, Profluent has done exactly that. 👏🏽👏🏽

Find out how they used generative #AI to create #OpenCRISPR , the world's first AI-generated (and open source) gene editor. nytimes.com/2024/04/22/tec…

🇩🇰 Danish #biotech Zealand Pharma knows that a strong digital strategy is key to success. That's why they chose to partner with Benchling.

By standardizing and centralizing their data, Zealand can streamline partnerships with CMOs and ultimately accelerate development — all on a

👋🏽 Say goodbye to manual copy-pasting… and hello to easy bulk cloning with our new combinatorial cloning tool! See how we’ve improved in silico cloning:

✔️ Visualize fragments and constructs as they’re being created
✔️ Clone using multiple methods, including Gibson, Golden

The #AI revolution is coming for #biotech ... but are R&D orgs ready?

Next week, @ShapeTX’s Head of AI Ron Hause will discuss their AI-based approach to discovery — along with advice for companies looking to set up AI-driven processes.

Register now 👇 bio.org/webinars/scien…

Did you know? With #BenchlingBioprocess , you can:

⚡ Create recipes with a drag-and-drop visual designer
⚡ Design experiments across process parameters
⚡ Improve efficiency with guided batch execution
⚡ Structure your data for #AI

Find out how to accelerate your process

Introducing: #AI -assisted search in Benchling! 🔎✨

Just type in what you’re looking for — using natural language queries — and the #LLM will configure nearly 100 search filters and parameters for you.

👀 See it in action! Join our May 7 webinar: benchling.com/whats-new?utm_…

A typical #biotech lab uses dozens to hundreds of instruments on a regular basis. So it’s easy to see how data can become disconnected and error-prone, especially if you’re relying on manual data entry.

That’s why we built #BenchlingConnect , a flexible platform for end-to-end

🎉 #BenchlingBioprocess is officially here! Today we’re excited to deliver an end-to-end solution for modern, high-throughput process development.

Now with Bioprocess, scientists can:
⚡ Shorten development cycles
⚡ Simplify tech transfer
⚡ Enable #AI -ready data

Find out

A great video highlighting not only the incredible innovation at Strand Therapeutics across the entire mRNA value chain, but also our amazingly talented workforce with a fantastic interview by Mae Kingsbury!

“As a PD scientist, if we have a more holistic view of our historical data, we can create more efficient plans for optimization strategies.”

Find out how Strand Therapeutics is using Benchling to shorten process development cycles — and build curative #mRNA therapeutics — by harnessing

Large crowd at #BPIeurope attending the LiveLabs tour... currentluly hearing about Benchling process management software offerings

You no longer need to be a machine learning shop to join the #AI party. #LLMs are ready for #biotech today.

Janet Matsen Alan Pierce explain how generative AI and LLMs can be used for more than drug discovery, throughout the entire R&D lifecycle: benchling.com/blog/biotech-i…

For all the hype around #AI and #ML , there's already real progress, esp for antibody drug discovery.

See Vega Shah's review of the innovators applying AI/ML to target identification, antibody design, and high-throughput screening and optimization. benchling.com/blog/antibody-…

Every industry is rushing to apply #AI — but why is this so critical for #biotech and why now? Today, our CEO Sajith and other industry experts joined National Academies’s workshop on AI and #automation to explain why.

▶️ Watch the recording: youtube.com/live/mRmjKZVkY…

Malay Gandhi, Head of Strategy & Corporate Development at #LECBacked Benchling recently joined the Vital Signs podcast to discuss the future of life sciences & real-world evidence, building & scaling software at Benchling, and more. Listen here: open.spotify.com/episode/68WJrs…

What do you lose if you don’t invest in #AI and #labautomation ? National Academies is bringing together industry experts, including our CEO Sajith, to discuss the strategic imperatives of investing in these technologies.

🎙️ Tune in on Wednesday: nationalacademies.org/event/41736_04…

“Large and small companies alike are adopting computational experiments at rapid clips.” Benchling's Malay Gandhi joined Jacob Effron Nikhil Krishnan on the Vital Signs podcast, to talk about the future of #biotech .

Here’s what he’s seeing:
✔️ There's a high willingness to

#AI and automated labs are already transforming #biotech — but what does that mean for your R&D? Join us for National Academies panel, where our CEO Sajith will discuss the strategic implications of these technologies.

Join virtually on April 3 at 2:45pm ET 👉🏽 nationalacademies.org/event/41736_04…